Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
Laura M. Spring(Massachusetts General Hospital), Aditya Bardia(UCLA Health), Rachel O. Abelman(Massachusetts General Hospital), Veerle Bossuyt(Harvard University), Paula D. Ryan(Massachusetts General Hospital), Beverly Moy(Global Cancer Institute), Therese M. Mulvey(Sidney Kimmel Cancer Center), Ana C. Garrido-Castro(Dana-Farber Cancer Institute), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Amy Comander(Harvard University), Sarah A. McLaughlin(Mayo Clinic in Arizona), Nadine Tung(Beth Israel Deaconess Medical Center), Leif W. Ellisen(Harvard University), Geoffrey Fell(Harvard University), Sara M. Tolaney(Harvard University), Shyamala Maheswaran(Massachusetts General Hospital), Aron S. Rosenstock(Harvard University), Lorenzo Trippa(Harvard University), Louise Ryan(University of Leicester), Bing Wu(Harvard University), Filipa Lynce(Institut Claudius Regaud), Edward Abraham(New York Medical College), Steven J. Isakoff(Harvard University)
Cited by 77
Related Papers
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Intensive Care Medicine|2003|2.9k